Raised concentration of soluble form of vascular endothelial cadherin and IL-23 in sera of patients with Behçet's disease

Modern Rheumatology

Volumn 20, Issue 2, 2010, Pages 154-159

  Habibagahi, Zahra ^a,b   Habibagahi, Mojtaba ^c   Heidari, Masoomeh ^a,c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Beh et's disease; IL 23; Soluble vascular endothelial cadherin

Indexed keywords

INTERLEUKIN 23; VASCULAR ENDOTHELIAL CADHERIN;

ADULT; AGED; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; IRIDOCYCLITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UVEITIS;

ADULT; AGED; ANTIGENS, CD; BEHCET SYNDROME; CADHERINS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERLEUKIN-23; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 77954758833     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0246-1     Document Type: Article

References (37)

1. Al-Mutawa SA, Hegab SM. Behcet's disease. Clin Exp Med. 2004;4:103-31.
2. Suzuki Kurokawa M, Suzuki N. Behcet's disease. Clin Exp Med. 2004;4:10-20.
3. Kone-Paut I, Yurdakul S, Bahabri SA, Shafae N, Ozen S, Ozdogan H, et al. Clinical features of Behcet's disease in children: an international collaborative study of 86 cases. J Pediatr. 1998;132:721-5.
4. Narikawa S, Suzuki Y, Takahashi M, Furukawa A, Sakane T, Mizushima Y. Streptococcus oralis previously identified as uncommon 'Streptococcus sanguis' in Behcet's disease. Arch Oral Biol. 1995;40:685-90.
5. Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Neutrophil activation in Behcet's disease. Clin Exp Rheumatol. 2001;19:S19-24.
6. Sahin S, Lawrence R, Direskeneli H, Hamuryudan V, Yazici H, Akoglu T. Monocyte activity in Behcet's disease. Br J Rheumatol. 1996;35:424-9.
7. Sahin S, Akoglu T, Direskeneli H, Sen LS, Lawrence R. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behcet's disease. Ann Rheum Dis. 1996;55:128-33.
8. Hordijk PL, Anthony E, Mul FP, Rientsma R, Oomen LC, Roos D. Vascular-endothelial-cadherin modulates endothelial monolayer permeability. J Cell Sci. 1999;112:1915-23.
9. Allport JR, Ding H, Collins T, Gerritsen ME, Luscinskas FW. Endothelial-dependent mechanisms regulate leukocyte transmigration: a process involving the proteasome and disruption of the vascular endothelial-cadherin complex at endothelial cell-to-cell junctions. J Exp Med. 1997;186:517-27.
10. Soeki T, Tamura Y, Shinohara H, Sakabe K, Onose Y, Fukuda N. Elevated concentration of soluble vascular endothelial cadherin is associated with coronary atherosclerosis. Circ J. 2004;68:1-5.
11. Jonsson MV, Salomonsson S, Oijordsbakken G, Skarstein K. Elevated serum levels of soluble E-cadherin in patients with primary Sjogren's syndrome. Scand J Immunol. 2005;62:552-9.
12. Dejana E, Spagnuolo R, Bazzoni G. Interendothelial junctions and their role in the control of angiogenesis, vascular permeability and leukocyte transmigration. Thromb Haemost. 2001;86:308-15.
13. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006;116:1218-22.
14. Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity. 2005;22:285-94.
15. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet. 1990;335:1078-80.
16. Krause I, Rosen Y, Kaplan I, Milo G, Guedj D, Molad Y, et al. Recurrent aphthous stomatitis in Behcet's disease: clinical features and correlation with systemic disease expression and severity. J Oral Pathol Med. 1999;28:193-6.
17. Krause I, Mader R, Sulkes J, Paul M, Uziel Y, Adawi M, et al. Behcet's disease in Israel: the influence of ethnic origin on disease expression and severity. J Rheumatol. 2001;28:1033-6.
18. Dalghous AM, Freysdottir J, Fortune F. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet's disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand J Rheumatol. 2006;35:472-5.
19. Kulaber A, Tugal-Tutkun I, Yentur SP, kman-Demir G, Kaneko F, Gul A, et al. Pro-inflammatory cellular immune response in Behcet's disease. Rheumatol Int. 2007;27:1113-8.
20. Ben AM, Houman H, Miled M, Dellagi K, Louzir H. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behcet's disease. Arthritis Rheum. 2004;50:2291-5.
21. Mizuki N, Meguro A, Tohnai I, Gul A, Ohno S, Mizuki N. Association of major histocompatibility complex Class I chainrelated Gene A and HLA-B Alleles with Behcet's disease in Turkey. Jpn J Ophthalmol. 2007;51:431-6.
22. Meguro A, Ota M, Katsuyama Y, Oka A, Ohno S, Inoko H, et al. Association of the toll-like receptor 4 gene polymorphisms with Behcet's disease. Ann Rheum Dis. 2008;67:725-7.
23. Hou S, Yang P, Du L, Zhou H, Lin X, Liu X, et al. SUMO4 gene polymorphisms in Chinese Han patients with Behcet's disease. Clin Immunol. 2008;129:170-5.
24. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715-25.
25. Chen Z, O'Shea JJ. Regulation of IL-17 production in human lymphocytes. Cytokine. 2008;41:71-8.
26. Maloy KJ. The Interleukin-23/Interleukin-17 axis in intestinal inflammation. J Intern Med. 2008;263:584-90.
27. von VS, Ley K. Homeostatic regulation of blood neutrophil counts. J Immunol. 2008;181:5183-8.
28. Lew W, Chang JY, Jung JY, Bang D. Increased expression of interleukin-23 p19 mRNA in erythema nodosum-like lesions of Behcet's disease. Br J Dermatol. 2008;158:505-11.
29. Chi W, Zhu X, Yang P, Liu X, Lin X, Zhou H, et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmol Vis Sci. 2008;49:3058-64.
30. Vestweber D, Winderlich M, Cagna G, Nottebaum AF. Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell Biol. 2009;19:8-15.
31. Garrido-Urbani S, Bradfield PF, Lee BP, Imhof BA. Vascular and epithelial junctions: a barrier for leucocyte migration. Biochem Soc Trans. 2008;36:203-11.
32. Turowski P, Martinelli R, Crawford R, Wateridge D, Papageorgiou AP, Lampugnani MG, et al. Phosphorylation of vascular endothelial cadherin controls lymphocyte emigration. J Cell Sci. 2008;121:29-37.
33. Gotsch U, Borges E, Bosse R, Boggemeyer E, Simon M, Mossmann H, et al. VE-cadherin antibody accelerates neutrophil recruitment in vivo. J Cell Sci. 1997;110:583-8.
34. Alcaide P, Newton G, Auerbach S, Sehrawat S, Mayadas TN, Golan DE, et al. p120-Catenin regulates leukocyte transmigration through an effect on VE-cadherin phosphorylation. Blood. 2008;112:2770-9.
35. Herren B, Levkau B, Raines EW, Ross R. Cleavage of betacatenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role for caspases and metalloproteinases. Mol Biol Cell. 1998;9:1589-601.
36. Villasante A, Pacheco A, Pau E, Ruiz A, Pellicer A, Garcia-Velasco JA. Soluble vascular endothelial-cadherin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome. Hum Reprod. 2008;23:662-7.
37. Gomez R, Simon C, Remohi J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology. 2002;143:4339-48.